Compare Rion Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 47,786 Million (Small Cap)
12.00
NA
0.00%
-0.24
9.11%
1.44
Revenue and Profits:
Net Sales:
7,948 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,097 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.71%
0%
37.71%
6 Months
49.6%
0%
49.6%
1 Year
52.52%
0%
52.52%
2 Years
35.14%
0%
35.14%
3 Years
100.21%
0%
100.21%
4 Years
60.76%
0%
60.76%
5 Years
42.08%
0%
42.08%
Rion Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.19%
EBIT Growth (5y)
13.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.89
Tax Ratio
26.68%
Dividend Payout Ratio
30.15%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.82%
ROE (avg)
8.50%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.07
EV to EBIT
6.83
EV to EBITDA
5.09
EV to Capital Employed
1.09
EV to Sales
0.98
PEG Ratio
1.80
Dividend Yield
NA
ROCE (Latest)
15.98%
ROE (Latest)
9.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
7,948.10
7,387.60
7.59%
Operating Profit (PBDIT) excl Other Income
1,675.60
1,312.90
27.63%
Interest
0.60
0.50
20.00%
Exceptional Items
0.00
-40.10
100.00%
Consolidate Net Profit
1,097.30
730.80
50.15%
Operating Profit Margin (Excl OI)
163.20%
130.50%
3.27%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 7.59% vs 2.35% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 50.15% vs 12.43% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
28,502.00
27,877.90
2.24%
Operating Profit (PBDIT) excl Other Income
5,765.80
5,276.40
9.28%
Interest
2.30
2.20
4.55%
Exceptional Items
0.00
-164.70
100.00%
Consolidate Net Profit
3,345.60
2,859.80
16.99%
Operating Profit Margin (Excl OI)
153.00%
144.70%
0.83%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 2.24% vs 8.36% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 16.99% vs 7.82% in Mar 2025
About Rion Co., Ltd. 
Rion Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






